Status:
WITHDRAWN
Enteric Coated Myfortic for Liver Transplant Recipients
Lead Sponsor:
The University of Texas Health Science Center, Houston
Collaborating Sponsors:
Novartis
Conditions:
Liver Transplantation
Eligibility:
All Genders
18-70 years
Phase:
PHASE4
Brief Summary
The purpose of this study is to replace the mycophenolate mofetil (Cellcept) which is our usual therapy after liver transplantation with sodium mycophenolic acid (Myfortic®) and to find out the effect...
Detailed Description
Mycophenolic Acid (MPA) has been shown to be an effective immune suppressant in organ transplantation. Its gastrointestinal side effects, however, have limited its use in liver transplantation (OLT). ...
Eligibility Criteria
Inclusion
- Liver transplant recipients
- Age: 18-70
- Capable of oral intake
Exclusion
- Hepatitis C Cirrhosis
- Hepatocellular Carcinoma T3
- Liver retransplantation
- Pregnancy
- Platelet count \<40,000
- White Blood Cell count (WBC) \<3,000
- Incapable of oral intake
- More than 30 days post op
Key Trial Info
Start Date :
September 1 2005
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
February 1 2009
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT00167492
Start Date
September 1 2005
End Date
February 1 2009
Last Update
December 9 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Memorial Hermann Hospital
Houston, Texas, United States, 77030